Predicting factors for disappearance of anti-mutated citrullinated vimentin antibodies in sera of patients with rheumatoid arthritis

References

• Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol. 1999;162(1):585–94.
   PubMed Web of Science ®Google Scholar
• Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101(1):273–81.
   PubMed Web of Science ®Google Scholar
• Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000;43(1):155–63.
   PubMed Web of Science ®Google Scholar
• Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B, Group BS. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis. 2004;63(9):1090–5.
   PubMed Web of Science ®Google Scholar
• Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis. 2005;64(2):196–201.
   PubMed Web of Science ®Google Scholar
• Wegner N, Lundberg K, Kinloch A, Fisher B, Malmstrom V, Feldmann M, et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev. 2010;233(1):34–54.
   PubMed Web of Science ®Google Scholar
• Bang H, Egerer K, Gauliard A, Luthke K, Rudolph PE, Fredenhagen G, et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum. 2007;56(8):2503–11.
   PubMed Web of Science ®Google Scholar
• Luime JJ, Colin EM, Hazes JM, Lubberts E. Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. Ann Rheum Dis. 2010;69(2):337–44.
   PubMed Web of Science ®Google Scholar
• Ursum J, Nielen MM, van Schaardenburg D, van der Horst AR, van de Stadt RJ, Dijkmans BA, et al. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther. 2008;10(1):R12.
   PubMed Web of Science ®Google Scholar
• Syversen SW, Goll GL, van der Heijde D, Landewe R, Lie BA, Odegard S, et al. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Ann Rheum Dis. 2010;69(2):345–51.
   PubMed Web of Science ®Google Scholar
• Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest. 2012;122(5):1791–802.
   PubMed Web of Science ®Google Scholar
• Kastbom A, Forslind K, Ernestam S, Geborek P, Karlsson JA, Petersson IF, et al. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial. Ann Rheum Dis. 2016;75(2):356–61.
   PubMed Web of Science ®Google Scholar
• Giles JT, Danoff SK, Sokolove J, Wagner CA, Winchester R, Pappas DA, et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis. 2014;73(8):1487–94.
   PubMed Web of Science ®Google Scholar
• Johnson C. Recent advances in the pathogenesis, prediction, and management of rheumatoid arthritis-associated interstitial lung disease. Curr Opin Rheumatol. 2017;29(3):254–9.
   PubMed Web of Science ®Google Scholar
• Bongartz T, Cantaert T, Atkins SR, Harle P, Myers JL, Turesson C, et al. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology. 2007;46(1):70–5.
   PubMed Web of Science ®Google Scholar
• Ishikawa N, Hattori N, Yokoyama A, Kohno N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig. 2012;50(1):3–13.
   PubMedGoogle Scholar
• Hu Y, Wang LS, Jin YP, Du SS, Du YK, He X, et al. Serum Krebs von den Lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients. Clin Respir J. 2017;11(3):337–45.
   PubMed Web of Science ®Google Scholar
• Oguz EO, Kucuksahin O, Turgay M, Yildizgoren MT, Ates A, Demir N, et al. Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study. Clin Rheumatol. 2016;35(3):663–6.
   PubMed Web of Science ®Google Scholar
• Doyle TJ, Patel AS, Hatabu H, Nishino M, Wu G, Osorio JC, et al. Detection of Rheumatoid Arthritis-Interstitial Lung Disease is Enhanced by Serum Biomarkers. Am J Respir Crit Care Med. 2015;191(12):1403–12.
   PubMed Web of Science ®Google Scholar
• Schett G, Emery P, Tanaka Y, Burmester G, Pisetsky DS, Naredo E, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: Current evidence and future directions. Ann Rheum Dis. 2016;75(8):1428–37.
   PubMed Web of Science ®Google Scholar
• Heinze G. A comparative investigation of methods for logistic regression with separated or nearly separated data. Stat Med. 2006;25(24):4216–26.
   PubMed Web of Science ®Google Scholar
• Barra L, Bykerk V, Pope JE, Haraoui BP, Hitchon CA, Thorne JC, et al. Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes. J Rheumatol. 2013;40(8):1259–67.
   PubMed Web of Science ®Google Scholar
• Guzian MC, Carrier N, Cossette P, de Brum-Fernandes AJ, Liang P, Menard HA, et al. Outcomes in recent-onset inflammatory polyarthritis differ according to initial titers, persistence over time, and specificity of the autoantibodies. Arthritis Care Res (Hoboken). 2010;62(11):1624–32.
   PubMed Web of Science ®Google Scholar
• Roland P, Mignot S, Bruns A, Hurtado M, Palazzo E, Hayem G, et al. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Res Ther. 2008;10(6):R142.
   PubMed Web of Science ®Google Scholar
• Fabris M, De Vita S, Blasone N, Visentini D, Pezzarini E, Pontarini E, et al. Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab. Autoimmun Highlights. 2010;1(2):87–94.
   PubMedGoogle Scholar
• Modi S, Soejima M, Levesque MC. The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses. Clin Exp Immunol. 2013;173(1):8–17.
   PubMed Web of Science ®Google Scholar
• Wunderlich C, Oliviera I, Figueiredo CP, Rech J, Schett G. Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-A longitudinal analysis. Semin Arthritis Rheum. 2017;46(6):709–14.
   PubMed Web of Science ®Google Scholar
• Ying H, Yang L, Qiao G, Li Z, Zhang L, Yin F, et al. Cutting edge: CTLA-4-B7 interaction suppresses Th17 cell differentiation. J Immunol. 2010;185(3):1375–8.
   PubMed Web of Science ®Google Scholar
• Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner EC, et al. Cutting edge: Anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol. 2008;180(2):688–92.
   PubMed Web of Science ®Google Scholar
• James E, Rieck M, Pieper J, Gebe JA, Yue BB, Tatum M, et al. Citulline specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy. Arthritis Rheum. 2014;66(7):1712–22.
   PubMed Web of Science ®Google Scholar
• Catalan D, Aravena O, Sabugo F, Wurmann P, Soto L, Kalergis AM, et al. B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRiib, which are modulated by anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010;12(2):R68.
   PubMed Web of Science ®Google Scholar
• van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A, Onnekink C, Schwarte CM, Verpoort KN, et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis. 2010;69(8):1554–61.
   PubMed Web of Science ®Google Scholar
• van de Stadt LA, van der Horst AR, de Koning MH, Bos WH, Wolbink GJ, van de Stadt RJ, et al. The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis. 2011;70(1):128–33.
   PubMed Web of Science ®Google Scholar
• Scherer HU, Huizinga TWJ, Kronke G, Schett G, Toes R. The B cell response to citrullinated antigens in the development of rheumatoid arthritis. Nat Rev Rheumatol. 2018;14(3):157–69.
   PubMed Web of Science ®Google Scholar
• Law SC, Street S, Yu CH, Capini C, Ramnoruth S, Nel HJ, et al. T-cell autoreactivity to citrullinated autoantigenic peptides in rheumatoid arthritis patients carrying HLA-DRB1 shared epitope alleles. Arthritis Res Ther. 2012;14(3):R118.
   PubMed Web of Science ®Google Scholar
• Scally SW, Petersen J, Law SC, Dudek NL, Nel HJ, Loh KL, et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med. 2013;210(12):2569–82.
   PubMed Web of Science ®Google Scholar
• Willis VC, Demoruelle MK, Derber LA, Chartier-Logan CJ, Parish MC, Pedraza IF, et al. Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. Arthritis Reum. 2013;65:2545–54.
   PubMedGoogle Scholar
• Reynisdottir G, Karimi R, Joshua V, Olsen H, Hensvold AH, Harju A, et al. Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheumatol. 2014;66(1):31–9.
   PubMed Web of Science ®Google Scholar
• Ohtsuki Y, Nakanishi N, Fujita J, Yoshinouchi T, Kobayashi M, Ueda N, et al. Immunohistochemical distribution of SP-D, compared with that of SP-A and KL-6, in interstitial pneumonias. Med Mol Morphol. 2007;40(3):163–7.
   PubMed Web of Science ®Google Scholar
• Sokai A, Tanizawa K, Handa T, Kanatani K, Kubo T, Ikezoe K, et al. Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis. ERJ Open Res. 2017;3(3):00019–2016.
   Google Scholar